Neurobehavioral effects of interferon-α in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions

Neuropsychopharmacology

Volumn 26, Issue 5, 2002, Pages 643-652

  Capuron, Lucile ^a   Gumnick, Jane F ^a   Musselman, Dominique L ^a   Lawson, David H ^a   Reemsnyder, Andrea ^a   Nemeroff, Charles B ^a   Miller, Andrew H ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depression; Fatigue; Melanoma; Neurotoxicity; Paroxetine; Sickness behavior

Indexed keywords

ALPHA INTERFERON; PAROXETINE;

ADULT; AGED; ANOREXIA; ANXIETY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FATIGUE; FEMALE; HUMAN; MALE; MELANOMA; MOOD; NEUROPSYCHIATRY; PAIN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTINEOPLASTIC AGENTS; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; MOOD DISORDERS; NEOPLASMS; PAROXETINE; PATIENTS; STATISTICS, NONPARAMETRIC;

EID: 0036199336     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00407-9     Document Type: Article

References (45)

1. Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis
2. The management challenges of chronic pain: The role of antidepressants
3. Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS
4. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy
5. Mania induced by withdrawal of treatment with interferon alfa
6. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat
7. Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments. An in vivo electrophysiologic study in the rat
8. Cytokines and sickness behavior
9. Primary hypothyroidism associated with interferon therapy of breast cancer
10. "Mini-mental State." A practical method for grading the cognitive state of patients for the clinician
11. Paroxetine in the treatment of chronic daily headache
12. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro
13. Treatment of chronic fatigue syndrome with nefazodone
14. Cytokine therapeutics: Lessons from interferon alpha
15. A rating scale for depression
16. Antidepressants and hypothalamic-pituitary-adrenocortical regulation
17. Sickness behavior as a new target for drug development
18. Mechanisms of sickness-induced decreases in food-motivated behavior
19. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
20. Depression in medically ill hospitalized older adults: Prevalence, characteristics, and course of symptoms according to six diagnostic schemes
21. Influence of acute and repeated interleukin-2 administration on spatial learning, locomotor activity, exploratory behaviors, and anxiety
22. Pathogenesis, natural history, treatment, and prevention of hepatitis C
23. Cytokines and brain function: Relevance to interferon-alpha-induced mood and cognitive changes
24. Antidepressants as analgesics: A review of randomized controlled trials
25. Negative immunoregulatory effects of antidepressants: Inhibition of interferon-gamma and stimulation of interleukin-10 secretion
26. The Hamilton Anxiety Scale: Reliability, validity and sensitivity to change in anxiety and depressive disorders
27. Persistent neurotoxicity of systematically administered interferon-alpha
28. Depression from interferon therapy in patients with hepatitis C
29. Effect of an SSRI antidepressant on fatigue and depression in seven hundred thirty-eight cancer patients treated with chemotherapy: A URCC CCOP study
30. Paroxetine for the prevention of depression induced by high-dose interferon alfa
31. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment
32. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice
33. Psychiatric complications of long-term interferon alfa therapy
34. The antinociceptive effect of fluvoxamine
35. Induction of hyperthyroidism by interferon-alpha-2b
36. Differential effect of chronic antidepressant treatments on lipopolysaccharide-induced depressive-like behavioural symptoms in the rat
37. The effects of interferon-alpha on the production and action of other cytokines
38. Treatment of neurotoxic side effects of interferon-alpha with naltrexone
39. Mood and cognitive side effects of interferon-alpha therapy
40. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome
41. Randomised, double-blind, placebo-controlled treatment trial of fluoxetine and graded exercise for chronic fatigue syndrome
42. The validity and reliability of the fatigue syndrome that follows glandular fever
43. Endotoxin produces a depressive-like episode in rats
44. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents